These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 11489799

  • 1. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
    Bornhäuser M, Thiede C, Platzbecker U, Jenke A, Helwig A, Plettig R, Freiberg-Richter J, Röllig C, Geissler G, Lutterbeck K, Oelschlagel U, Ehninger G.
    Clin Cancer Res; 2001 Aug; 7(8):2254-62. PubMed ID: 11489799
    [Abstract] [Full Text] [Related]

  • 2. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [Abstract] [Full Text] [Related]

  • 3. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 4. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
    Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A.
    Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
    [Abstract] [Full Text] [Related]

  • 5. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hägele M, Handgretinger R, Kanz L.
    Blood Cells Mol Dis; 2008 Feb; 40(1):13-9. PubMed ID: 17869547
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R.
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [Abstract] [Full Text] [Related]

  • 7. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.
    Bornhäuser M, Thiede C, Schuler U, Platzbecker U, Freiberg-Richter J, Helwig A, Plettig R, Röllig C, Naumann R, Kroschinsky F, Neubauer A, Ehninger G.
    Bone Marrow Transplant; 2000 Jul; 26(2):119-25. PubMed ID: 10918420
    [Abstract] [Full Text] [Related]

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 9. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Körbling MJ, Manning J, Romaguera J, Sarris A, Rodriguez, Hagemeister F, Mclaughlin P, Cabanillas F, Champlin RE.
    Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
    [Abstract] [Full Text] [Related]

  • 10. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
    Bornhäuser M, Theuser C, Soucek S, Hölig K, Klingebiel T, Blau W, Fauser A, Runde V, Schwinger W, Rutt C, Ehninger G.
    Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
    [Abstract] [Full Text] [Related]

  • 11. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F, Lang PJ, Ottinger H, Faul C, Bethge W, Handgretinger R, Bamberg M, Belka C.
    Int J Radiat Oncol Biol Phys; 2008 Feb 01; 70(2):523-8. PubMed ID: 17869449
    [Abstract] [Full Text] [Related]

  • 12. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH, Lee JH, Lee JH, Kim DY, Kim SH, Shin HJ, Lee YS, Kang YA, Seol M, Ryu SG.
    Biol Blood Marrow Transplant; 2009 Jan 01; 15(1):61-72. PubMed ID: 19135944
    [Abstract] [Full Text] [Related]

  • 13. Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
    Jillella AP, Shafer D, Klumpp TR, Emmons RV, Mangan KF.
    Am J Hematol; 2007 Jun 01; 82(6):419-26. PubMed ID: 17211845
    [Abstract] [Full Text] [Related]

  • 14. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM, Kami M, Mori S, Kanda Y, Suzuki R, Mineishi S, Takami A, Taniguchi S, Takemoto Y, Hara M, Yamaguchi M, Hino M, Yoshida T, Kim SW, Hori A, Ohashi Y, Takaue Y.
    Am J Hematol; 2007 Oct 01; 82(10):873-80. PubMed ID: 17570513
    [Abstract] [Full Text] [Related]

  • 15. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
    J Clin Oncol; 2008 Feb 01; 26(4):577-84. PubMed ID: 18086801
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease.
    Schetelig J, Kröger N, Held TK, Thiede C, Krusch A, Zabelina T, Dubiel M, Rick O, Bornhäuser M, Ehninger G, Zander AR, Siegert W.
    Haematologica; 2002 Mar 01; 87(3):299-305. PubMed ID: 11869943
    [Abstract] [Full Text] [Related]

  • 17. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2000 Oct 01; 26(7):711-6. PubMed ID: 11042650
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
    Saito T, Kanda Y, Kami M, Kato K, Shoji N, Kanai S, Ohnishi T, Kawano Y, Nakai K, Ogasawara T, Matsubara H, Makimoto A, Tanosaki R, Tobinai K, Wakasugi H, Takaue Y, Mineishi S.
    Clin Cancer Res; 2002 Apr 01; 8(4):1014-20. PubMed ID: 11948108
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia.
    Bertz H, Potthoff K, Finke J.
    J Clin Oncol; 2003 Apr 15; 21(8):1480-4. PubMed ID: 12697870
    [Abstract] [Full Text] [Related]

  • 20. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.
    Biol Blood Marrow Transplant; 2007 Jul 15; 13(7):790-805. PubMed ID: 17580257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.